Gameto Valuation, Funding & Investors
Gameto is valued at $149M as of May 2024.
Last Gameto valuation
$149M
Series B · May 2024
Last Gameto funding round
$44M
Series C · Aug 2025
Cumulative funding Gameto raised
$117M
across 5 funding rounds
Key investors in Gameto
Bold Capital Partners
Future Ventures
Insight Partners
RA Capital Management
Two Sigma Ventures
TA Ventures
About Gameto
Gameto is a New York-headquartered biotechnology company engineering stem cell-derived therapies for reproductive health disorders. Their platform reprograms human induced pluripotent stem cells into functional ovarian and endometrial cell lines using specific transcription factors that enable hormone production and response. Fertilo advances infertility treatments by enhancing IVF and egg freezing outcomes through improved egg maturation. Deovo develops organoids replicating the female reproductive tract for drug screening. Ameno addresses primary ovarian insufficiency and menopause via cell-based interventions. The company maintains partnerships with academic institutions like Columbia University and has initiated clinical studies for Fertilo in collaboration with reproductive clinics across Europe and the United States.
Founded
2020
HQ
New York City, NYWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$149M (May 2024)
Gameto Valuation
Gameto is currently valued at $149M, based on its Series B in May 2024.
The $33M round was led by RA Capital Management and Two Sigma Ventures.
Gameto valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| May 2024 | Series B | $149M |
Gameto Funding History
Gameto has raised a total of $117M across 5 funding rounds.
Gameto's first fundraising round was a $3M seed round in March 2020. The most recent completed round was a $44M Series C in August 2025.
Gameto funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Aug 2025 | Series C | Overwater Ventures (lead); Portfolia; Bold Capital Partners; The Pags Group; Future Ventures; Arcadia Investment Partners; Ingeborg Investments; RA Capital Management; Insight Partners; Pontiva Healthcare Partners; Two Sigma Ventures | $44M | - | Gameto is an Austin-based clinical-stage biotechnology company developing stem cell-derived therapies for women's health, particularly reproductive health including fertility, menopause, and family health. Its lead program, Fertilo, is an induced pluripotent stem cell-derived therapy using engineered ovarian support cells to mature egg cells outside the body, shortening IVF ovarian stimulation from two weeks of daily hormone injections to two to three days. Fertilo is currently in an ongoing Phase 3 trial evaluating safety and efficacy across up to 20 U.S. study sites and is used in clinics in Peru, Mexico, and Australia. On August 12, 2025, Gameto closed a $44 million Series C funding round led by Overwater Ventures, with participation from Insight Partners, RA Capital Management, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group (The Pags Group), Pontiva Healthcare Partners, Portfolia, and additional investors. This round brings Gameto's total capital raised since its 2021 founding to $127 million. The funding will support completion of the Phase 3 trial for Fertilo and preparation for global regulatory approvals, advancing the therapy toward U.S. FDA approval. Gameto was co-founded by Dr. Dina Radenkovic, a medical doctor-turned-entrepreneur, and Martin Varsavsky, founder of Inception Prelude, one of North America's largest fertility clinic networks. The company's cell engineering platform was developed with George Church's lab at Harvard Medical School. Investors highlighted Gameto's breakthrough science, potential for transformation in women's health akin to the birth control pill, and ability to build a consumer brand in biotech. |
| May 2024 | Series B | RA Capital Management (lead); Two Sigma Ventures (lead) | $33M | $149M | Gameto is a biotechnology company dedicated to advancing women's health through innovative fertility treatments. The company was founded by Dr. Dina Radenkovic and Martin Varsavsky and developed its technology platform in collaboration with George Church's lab at Harvard Medical School. Gameto's lead program, Fertilo, is a novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) designed to mature eggs outside of the body, with the potential to shorten IVF cycles from 10-14 days to 2-3 days and eliminate the need for hormonal injections. On May 29, 2024, Gameto closed an oversubscribed $33 million Series B financing round led by Two Sigma Ventures and RA Capital, with a post-money valuation of $149.02 million. The round included participation from existing investors Insight Partners, Future Ventures, and BOLD Capital Partners, as well as new investors including Olivia Walton's Ingeborg Investments, Stacey Bendet Eisner, and Chelsea Hirschhorn. This brought Gameto's total capital raised to $73 million as of that date. The Series B funding supports clinical development of Fertilo in the U.S., post-market surveillance outside the U.S., and commercial operations. Gameto had already received FDA green light to proceed with Phase 3 trials and had begun commercial launches in Australia and Latin America prior to the Series B round. |
| Sep 2022 | Undisclosed stage | Insight Partners (lead); Bold Capital Partners; Future Ventures; TA Ventures; Arcadia Partners; Korify Capital; Plum Alley; Gaingels; Myelin VC | $17M | - | Gameto is a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system. On September 14, 2022, Gameto raised $17 million from Insight Partners, Future Ventures, Arcadia Investment Partners, Bold Capital Partners, Plum Alley, Myelin VC, TA Ventures, Gaingels, Korify Capital, and other existing investors. This round brought total capital raised since inception to $40 million. |
| Jan 2022 | Series A | Future Ventures (lead); Bold Capital Partners; Overwater Ventures; Lux Capital; TA Ventures; Robert Nelsen; Plum Alley; Anne Wojcicki | $20M | - | Gameto is a biotechnology company developing stem cell-derived therapies for reproductive health, focusing on women's health issues like fertility and menopause. Its platform includes programs such as Fertilo, which treats oocytes outside the body to improve IVF and egg freezing outcomes by increasing maturation rates and oocyte quality, and Deovo for drug discovery targeting ovarian aging. In January 2022, Gameto raised $20 million in a Series A funding round led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures, Robert Nelsen of ARCH Venture Partners, and Anne Wojcicki of 23andMe. This followed a $3 million seed round in March 2020 from investors including Jack Abraham of Atomic, SALT Fund, FJ Labs, Dan Rose, and Brian Armstrong of Coinbase. The funds from the Series A were aimed at advancing Gameto's ovarian therapeutics platform to address menopause and assisted fertility. Gameto, founded in 2020 and headquartered in Austin, TX (with early operations in New York), was co-founded by Dr. Dina Radenkovic and Martin Varsavsky, who also founded the large fertility clinic network Inception Prelude. The company leverages cell engineering technology developed with George Church's lab at Harvard Medical School. Subsequent rounds included a $33 million oversubscribed Series B in May 2024 led by Two Sigma Ventures and RA Capital, bringing total funding to $73 million, to support clinical development of Fertilo in the U.S. and commercial operations. Later, in 2025, Gameto closed a $44 million Series C led by Overwater Ventures (with some sources citing Future Ventures), pushing total funding to $127 million, to complete Phase 3 trials for Fertilo, which has approvals outside the U.S. and reported five live births and over 20 pregnancies. |
| Mar 2020 | Seed | Jack Abraham; Brian Armstrong; FJ Labs; SALT Fund; Dan Rose | $3M | - | - |
Who has invested in Gameto?
25 investors have backed Gameto across its funding rounds, including Bold Capital Partners, Future Ventures, Insight Partners, RA Capital Management, Two Sigma Ventures and TA Ventures.
Lead investors include Overwater Ventures, RA Capital Management, Two Sigma Ventures, Insight Partners and Future Ventures.
Gameto Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| Los Angeles, CA | 3 | Participant | Jan 2022 | |
| San Francisco, CA | 3 | Lead | Jan 2022 | |
| San Francisco, CA | 2 | Lead | Jan 2022 | |
 Frankfurt | 2 | Participant | Jan 2022 | |
| Boston, MA | 2 | Lead | May 2024 | |
| New York City, NY | 2 | Participant | Jan 2022 | |
| New York City, NY | 2 | Lead | Sep 2022 | |
| New York City, NY | 2 | Lead | May 2024 | |
| San Francisco, CA | 1 | Participant | Aug 2025 | |
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small} The Pags Group | Boston, MA | 1 | Participant | Aug 2025 |
| San Francisco, CA | 1 | Participant | Mar 2020 | |
| San Francisco, CA | 1 | Participant | Mar 2020 | |
| New York City, NY | 1 | Participant | Mar 2020 | |
This data is available for Pro users. Sign up to see all 25 Gameto investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialGameto Competitors
Gameto competitors include listed companies like Conexeu Sciences, Humacyte and Huons Co, and private ones like Brainsgate, INCOG BioPharma and Sahajanand Medical Technologies.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| United States | Publicly listed | - | ($4M) | $151M | - | |
| United States | Publicly listed | $2M | ($25M) | $160M | 47.2x | |
 Caesarea | Private | - | - | $161M | - | |
| United States | Private | - | - | $168M | - | |
 South Korea | Publicly listed | $452M | $58M | $170M | - | |
 Surat | Private | - | - | $128M | - |
Gameto Public Comps
Gameto is still privately-owned, but its public comps include Lucid Diagnostics, PhotoCure, Cereno Scientific, Tenaya Therapeutics, Vytrus Biotech, NRX Pharmaceuticals, Mycenax Biotech, Quanterix, BioInvent International and Conexeu Sciences.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $5M | ($58M) | 29.9x | 24.0x | (2.4x) | (2.8x) | |||
| $57M | $3M | 2.3x | 2.0x | 49.1x | 18.7x | |||
| - | ($8M) | - | - | (21.6x) | (14.3x) | |||
| - | ($85M) | - | 26.6x | (0.9x) | (0.8x) | |||
| $10M | $5M | 15.1x | - | 30.8x | - | |||
| $1M | ($28M) | 99.2x | 27.6x | (4.4x) | (4.8x) | |||
| $23M | ($4M) | 7.5x | 0.6x | (39.8x) | - | |||
| $139M | ($102M) | 0.6x | 0.6x | (0.9x) | (1.3x) | |||
This data is available for Pro users. Sign up to see all Gameto competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Gameto
| When was Gameto founded? | Gameto was founded in 2020. |
| Where is Gameto headquartered? | Gameto is headquartered in New York City, NY, United States. |
| Is Gameto publicly listed? | No, Gameto is a private, VC-backed company. |
| What is Gameto's valuation? | Gameto was last valued at $149M in its Series B in May 2024. |
| How much funding has Gameto raised? | Gameto has raised $117M across 5 funding rounds. |
| What was Gameto's last funding round? | Gameto's last funding round was a $44M Series C in August 2025, led by Overwater Ventures. |
| Who are Gameto's investors? | Gameto's investors include Bold Capital Partners, Future Ventures, Overwater Ventures, TA Ventures, RA Capital Management, Plum Alley, Insight Partners, Two Sigma Ventures, Portfolia, The Pags Group and 15 others. |
| Which companies are comparable to Gameto? | Companies comparable to Gameto include Conexeu Sciences, Humacyte, Brainsgate, INCOG BioPharma, Huons Co and Sahajanand Medical Technologies. |
See companies similar to Gameto
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.